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Background: Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) play a central role in the endothelial
permeability regulation and dysfunction, which is associated with the development of sepsis and acute lung injury/
acute respiratory distress syndrome (ALI/ARDS). The aim of this study is to assess the diagnostic and prognostic
values of TF and TFPI in patients with sepsis and sepsis-induced ARDS.
Methods: A total of 62 patients with sepsis, 167 patients with severe sepsis and 32 healthy volunteers were
enrolled in this prospective observational study. TF and TFPI levels were measured by enzyme-linked immunosorbent
assay (ELISA).
Results: Patients with sepsis-induced ARDS showed significantly higher median levels of TF compared with patients
without ARDS (1425.5 (1019.9 to 2595.2) pg/ml vs 916.2 (724.1 to 1618.2) pg/ml, P < 0.001), and compared with sepsis
patients (943.5 (786.4 to 992.4) pg/ml, P < 0.001) on the day of admission. However, there was no significant difference
between sepsis patients and healthy subjects, or between septic shock and non-septic shock patients (P > 0.05). The
AUC of TF for the diagnosis of sepsis-induced ARDS was 0.749 (95% confidence interval (CI) 0.675-0.822). Plasma TF
levels in the non-survivors of severe sepsis were significantly higher than those of survivors (1618.6 (1017.1 to 2900.8)
pg/ml vs. 979.9 (757.2 to 1645.5) pg/ml, P < 0.001), and multivariate logistic regression showed the plasma value of TF
was the independent predictor for 30-day mortality in patients with severe sepsis (P = 0.0022, odds ratio (OR) = 1.41,
95% CI 1.24-1.69). The AUC of TF for predicting 30-day mortality in severe sepsis patients was 0.718 (95% CI 0.641-0.794).
However, there was no significant difference in the plasma TFPI values among the healthy control, sepsis and severe
sepsis groups (P > 0.05).
Conclusions: Our data showed that tissue factor is a valuable diagnostic biomarker for the diagnosis of sepsis-induced
ARDS. Moreover, tissue factor is a strong prognostic marker for short-term mortality in severe sepsis and sepsis-induced
ARDS patients.
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Despite advances in the development of numerous drugs
and supportive care therapies, severe sepsis remains an
unconquered challenge for clinical investigators and
physicians with an unacceptable high mortality rate of
28% to 50%. Sepsis is the most common cause of death
in the non-cardiac intensive care unit (ICU) [1]. The
pathogenesis of sepsis is not precisely understood; emer-
ging evidence suggested that an exaggerated systemic
host inflammation and coagulation response to infec-
tious pathogens led to microvascular thrombosis and
multiple organ dysfunction syndromes (MODS). In re-
cent years, mounting empirical evidence supported that
an extensive cross-talk between the inflammation and
coagulation systems played a pivotal role in the patho-
genesis of microvascular failure and subsequent multiple
organ failure, as a result of severe infection [2]. Pro-
inflammatory cytokines lead to activation of coagulation
and downregulate the physiologic anticoagulant path-
ways; conversely, activated coagulation proteases modu-
late the inflammatory response [3, 4]. Many clinical
studies found that virtually all septic patients had coagu-
lation abnormalities. The clinical manifestations of co-
agulation abnormalities were highly variable, depending
on the illness severity and duration time of infection.
Most sepsis patients only had clinically insignificant
changes in platelet count. However, uncontrollable clot
formation and bleeding in overt disseminated intravas-
cular coagulation (DIC) was seen in a few severe sepsis
and septic shock patients. It is clearly established that
the overexpression of TF or the imbalance between TF
and TFPI was closely related with the mechanisms in-
volved in the pathological derangement of coagulation in
septic patients [5–7].
TF, a transmembrane glycoprotein, is expressed by
various cell types [8]. In endotoxemic and septic ani-
mals, TF expression is increased not only in monocytes-
macrophages but also in tissue cells, e.g. lung and kidney
epithelial cells, and brain astrocytes [9, 10]. Many studies
have suggested that the aberrant in vivo expression of
TF plays a pivotal role in sepsis-associated blood clotting
change, as indicated by the following observations:
1) the impairment of the TF pathway by various
means prevents coagulation abnormalities and lethality in
animal models of sepsis or endotoxemia [9–11]; 2) the
plasma levels of TF are increased in septic patients and
generally associated with raised concentrations of
markers of clotting activation [9, 11, 12]. Normally,
thrombin generation via the TF pathway is rapidly con-
trolled by TFPI, which is an endogenous inhibitor of
TF-associated coagulation cascade [13]. TFPI directly
inhibits activated factor X and, in a factor-dependent
manner, produces feedback inhibition of the factor
VIIa/TF complex. It has been reported that the lowerlevels of TFPI are strongly correlated with organ dysfunc-
tion as well as worse outcome of severe sepsis [14].
Considering the potential association of an activated
coagulation system with sepsis pathophysiology, particu-
larly the role of TF pathway as an important initiator
of the coagulation system, TF and TFPI are excellent
candidate biomarkers for early diagnosis of sepsis,
risk stratification, and evaluation of prognosis in sep-
tic patients. Although some clinical studies found the
plasma TF and TFPI levels are significantly changed
in septic patients and correlated with the severity of
sepsis, the results were controversial because of small
sample size. Thus, the objective of this study was to
assess the prognostic and diagnostic value of plasma
TF and TFPI levels in patients with sepsis, sepsis-




From March 2010 to December 2013, a total of 62
patients with sepsis, 167 patients with severe sepsis ad-
mitted into the Emergency department and ICU of
Zhongshan Hospital, Fudan University (Shanghai, China)
were included. Definitions of sepsis, severe sepsis and
ARDS were in accordance with the American College of
Chest Physicians/Society of Critical Care Medicine
Consensus Conference, the American-European Consensus
Conference statements and the new (Berlin) definition
[15–17]. Severe sepsis subjects enrolled had either
organ dysfunction or septic shock. Exclusion criteria
included age < 18 years, pregnancy, diffuse alveolar
hemorrhage, severe chronic respiratory disease, direct-
ive to withhold intubation, severe chronic liver disease
(defined as a Child-Pugh score of > 10), malignancy,
using of chronic high-dose immunosuppressive ther-
apy (steroids with equivalent prednisone ≥ 0.5 mg/kg
per day or cytotoxic agents for immunologic disorders)
and Acquired Immune Deficiency Syndrome (AIDS)
patients. Clinical and demographic data at baseline, in-
cluding Acute Physiology and Chronic Health Evaluation
(APACHE) II scores, organ failure, previous health status,
hospital and ICU mortality were obtained after the pa-
tient met inclusion criteria. This study was approved by
the Ethic Committee of Zhongshan Hospital, Fudan
University, Shanghai, China (Record no: 2006–23). In-
formed consent was obtained from subjects or from their
legal surrogates before enrollment.
Data collection and the TF/TFPI measure
Demographic and clinical data were recorded on the
study enrollment and included age, gender, PaO2/FiO2 and
APACHE II score. In addition, the degree of hypoxemia
of ARDS was divided into mild (200 < PO2/FiO2 ≤ 300),
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FiO2 ≤ 100) according to the Berlin definition. Blood
samples for determination of TF/TFPI were collected
at enrollment for all participants and were centri-
fuged within the next 1 hour. Plasma samples were
frozen at −80 °C for further analysis. Levels of TF/TFPI
were measured using an ELISA kit according to the man-
ufacturer’s instructions (Human TF/TFPI ELISA Kit,
R&D, Minnesota, USA). The plates were read at a wave-
length of 450 nm with an automatic ELISA reader and
the assay did not cross-react with other related protein.
Statistical analysis
Continuous variables were presented as median (inter-
quartile range), and categorical variables as numbers and
percentages. For multi-group comparisons, Kruskal-
Wallis one-way analysis of variance was applied, and
two-group comparisons were performed nonparametri-
cally using the Mann–Whitney U test. To compare the
predictive value of TF, TFPI and APACHE II score for
sepsis, severe sepsis, septic shock, sepsis-induced ARDS
and 30-day mortality, receiver operating characteristic
(ROC) curves were constructed and the areas under
the ROC curves (AUCs) were determined. On the
basis of optimal thresholds determined according to
ROC curve analysis, prognostic parameters (sensitivity,
specificity) were also calculated. The optimal cutoff
value was determined when the Youden index reached
the maximum value. Logistic regression was assessed
by univariate and multivariate analysis to identify inde-
pendent predictors of outcome. The survival estimate
was based on the Kaplan-Meier product-limit method,
and comparisons of survival distributions were based
on the log-rank test. All probabilities were two tailed
and P < 0.05 was regarded as significant. Data were
statistically analyzed with SPSS 17.0 software (SPSS Inc.,
Chicago, IL, USA).Table 1 The baseline characteristics of the study populations
Number Age (Years) Male
Healthy control 32 62 (56–66) 18 (56
Sepsis patients 62 65 (56–75.25) 35 (56
Severe sepsis patients 167 65 (55–74) 101 (6
Sepsis-induced ARDS 73 64 (53.5-72) 45 (61
Non-ARDS 94 65 (56–76) 56 (59
Septic shock 54 66 (56–76) 33 (61
Non-septic shock 113 65 (55–71) 68 (60
Survivor 98 65 (56–74) 93 (60
Non-survivor 69 65 (47–73) 42 (60
Gram positive 42 63 (54.5-73) 24 (57
Gram negative 56 65 (54.25-74.75) 30 (60Results
Study population characteristics
A total of 62 sepsis and 167 severe sepsis patients in the
Emergency department and ICU of Zhongshan Hospital
and 32 healthy controls were enrolled in this study.
Severe sepsis patients were classified into ARDS and
non-ARDS groups, septic shock and non-septic shock
groups, survivor and non-survivor groups according to
the illness severity and 30-day survival. The baseline
characteristics of the study population were presented in
Table 1. No significant difference was found in age and
gender among the three groups (healthy control, sepsis
and severe sepsis groups). The APACHE II scores in the
severe sepsis, sepsis-induced ARDS, septic shock, non-
survivor patients were significantly higher than those in
patients with sepsis, non-ARDS, non-septic shock and
survivor respectively (P < 0.05). Sixty-five percent of se-
vere sepsis patients had positive microbial isolates: 39%
of the positive isolates were gram-positive, 52% gram-
negative, and 9% fungal. In patients with positive iso-
lates, the most common gram-positive organisms were
Staphylococcus aureus and Staphylococcus epidermidis;
the most common gram-negative organisms were Acine-
tobacter baumannii and Escherichia coli.
The plasma TF values in sepsis-induced ARDS patients
Table 2 showed the plasma levels of TF and TFPI in the
healthy subjects, sepsis and severe sepsis patients. There
were no statistical differences in the TFPI levels among
the healthy control, sepsis and severe sepsis groups
(P > 0.05). The plasma TF levels of patients with se-
vere sepsis were markedly higher than those in both
healthy controls and sepsis patients (P < 0.001), whereas
there was no significant difference between the healthy
subjects and sepsis patients (P > 0.05). In the sub-group
analysis, patients with sepsis-induced ARDS had signifi-
cantly higher median levels of TF compared with patients(N,%) APACHE II score P value (APACHE II score)
.3%) 3 (3–5)
.5%) 10 (9–12) P < 0.001(severe sepsis vs sepsis)
0.5%) 15 (12–20)
.6%) 16 (13–21) P = 0.002 (ARDS vs non-ARDS)
.6%) 14 (12–16.5)
.1%) 17.5 (14–21) P = 0.003 (shock vs non-shock)
.2%) 14 (12–17)
.2%) 12 (14–16) P < 0.001 (survivor vs non-survivor)
.9%) 18 (14–21)
.1%) 15 (12–20) P = 0.94 (G+vs G−)
.7%) 15 (12–19)
Table 2 The plasma values of TF and TFPI in healthy, sepsis and severe sepsis groups
Number TF (pg/ml) TFPI (pg/ml) P value (TF)
Healthy control 32 870.1 (779.2-1049.7) 248612.6 (193776.8-339925.5) P = 0.33 (healthy control vs sepsis)
Sepsis 62 943.5 (786.4-992.4) 300279.5 (181779.2-349692.7)
Severe sepsis 167 1045.7 (834.2-2156.6) 314059.7 (203476.4-317680.2) P = 2.11 × 10−4 (severe sepsis vs sepsis)
Sepsis-induced ARDS 73 1424.5 (1019.9-2595.2) 317477.4 (195388.2-317783.1) P = 3.66 × 10−8 (ARDS vs Non-ARDS)
Non-ARDS 94 916.2 (724.1-1618.2) 311405.5 (179876.1-352123.9)
Septic shock 54 1182.3 (834.2-2164.8) 316321.6 (190792.5-350043.2) P = 0.541 (septic shock vs non-shock)
Non-shock 113 1022.7 (798.6-2166.5) 309326.5 (171236.8-304562.7)
Survivor 98 979.9 (757.2-1645.5) 336934.1 (198865.2-343567.5) P = 9.25 × 10−6 (survivor vs non-survivor)
Non-survivor 69 1618.6 (1017.1-2900.8) 335995.4 (181790.1-340065.2)
Gram positive 42 1113.7 (831.1-2352.8) 318765.9 (203712.4-321100.6) P = 0.419 (G+ vs G−)
Gram negative 56 1521.6 (911.2-2464) 320135.5 (190006.3-356432.5)
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(724.1 to 1618.2) pg/ml, P < 0.001) and compared with
sepsis patients (943.5 (786.4 to 992.4) pg/ml, P < 0.001) at
the time of diagnosis, however there was no significant
difference between septic shock and non-septic shock pa-
tients (P > 0.05) (Fig. 1). The AUC for TF in relation to
the diagnosis of sepsis-induced ARDS from non-ARDS
patients was 0.749 (95% CI 0.675-0.822) (Fig. 2). At a cut-
off point > 1005.8 pg/ml, TF provided specificity of 80.8%
and sensitivity of 61.7% for the diagnosis of sepsis-
induced ARDS.
Then, the plasma TF levels in 60 sepsis-induced ARDS
patients were measured on the 1st, 3rd and 7th day after
ARDS diagnosis. On the day of admission, the TF
plasma levels in non-survivors of ARDS patients were
significantly elevated compared with those in survi-
vors of ARDS patients (2163.3 pg/ml vs. 1666.6 pg/ml,
P = 0.00013). The TF levels in ARDS survivor wereFig. 1 The plasma values of TF in different subgroup patients with severe s
median levels of TF compared with patients without ARDS at the time of dia
septic shock and non-septic shock groups. The TF plasma values in the non
survivors (P < 0.001)declined obviously on the 3rd and 7th day; however, the
TF values in the non-survivors were increased continu-
ally on the 3rd and 7th day (Fig. 3). Then, all sepsis-
induced ARDS patients were classified into mild (n = 11),
moderate (n = 21) and severe (n = 41) groups according
to the degree of hypoxemia. There were significant differ-
ences in TF value among the mild, moderate and severe
ARDS groups (Table 3). The TF values of the severe and
moderate groups were significantly higher than those of
the mild group (P < 0.001) (Table 3). All these results
indicated that the plasma levels of TF were obviously
associated with the illness severity and outcome in
sepsis-induced ARDS patients.
The association between the plasma TF levels and
outcome of severe sepsis
Moreover, our results also showed that the TF plasma
values were associated with the outcome of severe sepsis.epsis. Patients with sepsis-induced ARDS had significantly higher
gnosis (P < 0.001), however there was no significant difference between
-survivors of severe sepsis were significant higher than those in the
Fig. 2 The ROC curve for TF in relation to the diagnosis of
sepsis-induced ARDS. The AUC for TF in relation to the diagnosis
of sepsis-induced ARDS from non-ARDS patients was 0.749
(95% CI 0.675-0.822)
Table 3 The TF plasma values in the mild, moderate and severe
sepsis-induced ARDS patients
Number TF (pg/ml) P value
Mild ARDS 11 967.7(897.0-1008.7) P = 0.0002
(mild vs moderate)
Moderate ARDS 21 1234.0(1076.9-1666.6) P = 0.001
(moderate vs severe)
Severe ARDS 41 2170.0(1234.3-3340.0) P = 2.25 × 10-6
(mild vs severe)
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sepsis were significant higher than those in the survi-
vors (1618.6 (1017.1- 2900.8) pg/ml vs. 979.9 (757.2-
1645.5) pg/ml, P < 0.001) (Table 1, Fig. 1). Univariate
analysis showed that admission plasma TF levels and
the APACHE II scores were the both predictors of
30-day mortality in patients with severe sepsis. MultivariateFig. 3 The plasma levels of TF on the 1st, 3rd, 7th day of
sepsis-induced ARDS patients. On the day of admission, the TF
plasma levels in non-survivors of ARDS patients were significantly
elevated compared with those in survivors of ARDS patients
(P = 0.00013). The TF levels in ARDS survivor were declined obviously
on the 3rd and 7th day; however, the TF values in the non-survivors
were increased continually on the 3rd and 7th daylogistic regression analysis showed the TF levels remained
the independent predictor for mortality after adjust-
ment for APACHE II scores (P = 0.0022, OR = 1.41,
95% CI 1.24-1.69). The ROC was drawn to evaluate
the value of TF to predict 30-day mortality. The AUC of
TF for predicting 30-day mortality in septic patients was
0.718 (95% CI 0.641-0.794), slightly lower than that of
the APACHE II scores (0.804 (95% CI 0.730-0.878),
P < 0.05). The AUC of TF in combination with the
APACHE II scores was 0.832 (95% CI 0.764-0.900),
which was more statistically significant compared with
TF alone (Fig. 4). The optimal cut off value for predicting
death was > 1033.9 pg/ml, which gave specificity of 62.5%
and sensitivity of 71.1%. A Kaplan-Meier curve was
drawn according to the value of 1033.9 pg/ml for TF as a
cutoff point to describe death over 30 days of follow-up
(Fig. 5).
Discussion
Several clinical studies found the plasma TF levels were
significantly changed in septic and ARDS patients;Fig. 4 The ROC curve for TF, APACHE II in relation to the outcome
of severe sepsis patients. The AUC of TF for predicting 30-day
mortality in septic patients was 0.718, slightly lower than that
of APACHE II scores 0.804. The AUC of TF in combination with
the APACHE II scores was 0.832, which was more statistically
significant compared with TF alone
Fig. 5 The survival probability of severe sepsis patients by TF value.
A Kaplan-Meier curve was drawn according to the value of
1033.9 pg/ml for TF as a cutoff point to describe death over
30 days of follow-up
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Our current study with a relatively large-size sample
demonstrated that patients with sepsis-induced ARDS
had markedly high tissue factor levels compared with
patients without ARDS. And, the plasma levels of TF
were significantly associated with the illness severity and
outcome in sepsis-induced ARDS patients. Moreover,
our results also indicated that the plasma values of TF in
the non-survivors with severe sepsis were obviously
higher than those in the survivors. Univariate analysis
showed both plasma TF levels and APACHE II score
were the predictors for 30-day mortality in patients with
severe sepsis and further logistic regression analysis re-
vealed the TF levels were independent of APACHE II
score. APACHE II score in the septic shock was signifi-
cantly higher than those in patients with non-septic
shock. However, there was no significant difference be-
tween septic shock and non-septic shock patients in the
plasma tissue factor levels.
Several studies proved that the plasma concentration
of TF was significantly higher in both ARDS and severe
sepsis patients [18, 19]. One prospective cohort study
consisting of 113 patients (27 patients with ARDS, 31
patients at risk but not developing this syndrome, and
55 patients without ARDS) found that the values of TF
in patients with ARDS were significantly elevated com-
pared with those measured in other groups [20]. The TF
levels were significantly correlated with lung injury
score. In addition, TF dependent coagulation pathway of
plasma was extensively activated in patients with ARDS.
Further supporting data demonstrated that the pro-
coagulant properties of broncoalveolar lavage fluid (BALF)
from ARDS patients were the result of TF induction, andfurther indicated that BALF neutrophils were a main
source of TF in intra-alveolar fluid [21]. All these results
were in accord with the current study that showed the
plasma levels of TF were associated with the illness severity
and outcome in sepsis-induced ARDS patients. TF was a
valuable diagnostic biomarker for the diagnosis of sepsis-
induced ARDS. In addition, TF was a strong prognostic
marker for short-term mortality in severe sepsis and
sepsis-induced ARDS patients.
Activation of coagulation through the TF-dependent
pathway has been suggested to be a central mechanism
in the pathogenesis of ALI and other inflammatory
conditions including pneumonia, sepsis, and ventilator-
induced lung injury [22]. Extravascular fibrin deposition
is a common characteristic of the acute inflammatory re-
sponse and is prominent in the alveolar compartment of
patients with ARDS. Fibrin deposition in the lung is reg-
ulated by a balance of locally expressed pathways of co-
agulation and fibrinolysis [23]. Although activation of
the contact and intrinsic pathway occurs, fibrin depos-
ition within the injured alveolar compartment is mainly
initiated by locally increased activity of the extrinsic co-
agulation pathway. Tissue factor is the initiator of the
extrinsic coagulation pathway. Previous studies found
that in the early stage of acute lung injury and inflam-
mation, TF protein levels were significantly increased in
the alveolar spaces of the lung [24]. During sepsis and
ARDS, a variety of stimuli such as proinflammatory cy-
tokines and shear stress induce TF expression on mono-
cytes and endothelial cells. When TF expresses on the
cell surface, factor VIIa binds to TF, forming the bianry
of TF/FVIIa. Then, the bianry of TF/FVIIa binds to fac-
tor X, forming the ternary TF/FVIIa /FXa complexes,
and leading the eventual thrombin generation and fibrin
formation. It is well established that TF has widespread
implications in the human body beyond its function in
the coagulation system. As an intermediate for factor
VIIa, TF also played an important role in the intracellu-
lar signaling of established inflammatory pathways.
These effects were mediated by protease-activated recep-
tors (PARs), members of the G protein-coupled receptor
family that activate mitogenactivated protein kinase and
NF-κB signaling. Until now, a total of four subtypes of
PARs have been identified. PARs form the molecular link
between coagulation and inflammation. Among them,
the PAR1 and PAR2 were implicated in the acute inflam-
matory response. [25]. Pawlinski and Mackman [7]
proved that genetically modified mice expressing low
levels of TF exhibited reduced interleukin-6 expression
and increased survival in a mouse model of endotoxemia
compared with control mice.
Some animal experiments and clinical studies proved
the benefit of the early blockade of the TF-VIIa-activated
coagulation system in reducing both systemic and
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proving lung physiology, histological results and even sur-
vival. He et al. found that anti-human TF antibody
attenuated the severity of lung tissue injury, reduced alveo-
lar fibrin deposition and protein concentration in BALF
using ARDS model induced by intestinal ischemia-
reperfusion [26, 27]. In addition, Welty-Wolf and col-
leagues found that systemic blockade of factor X binding
to the tissue factor-factor VIIa complex could attenuate fi-
brinogen depletion, decrease proinflammatory cytokines
and prevent sepsis-induced damage to the lungs [28].
Normally, thrombin generation via the TF pathway is
rapidly controlled by TFPI [13]. TFPI is the main regula-
tor in the initial step of the coagulation cascade medi-
ated by TF, which binds to coagulation factors Xa, VIIa,
TF and forms an inactive complex. It has been reported
that the imbalance between the levels of TF and TFPI
seems to play a pivotal role in the pathogenesis of sepsis
and ARDS. A prospective, cohort study recruited 31
consecutive patients with sepsis, classified as 15 survi-
vors and 16 non-survivors, and 10 healthy volunteers
served as controls. They found activation of TF-
dependent coagulation pathway not adequately balanced
by TFPI has important roles in sustaining DIC and sys-
temic inflammatory response syndrome [29]. However,
in our sample the plasma TFPI values among the healthy
controls, sepsis and severe sepsis groups were not sig-
nificantly different.
There were several limitations to our study. First, the
ARDS patients enrolled in the current study were sepsis-
induced patients. We did not measure the TF levels in
other risk factors induced-ARDS patients. Second, the
absence of a single-objective gold standard for diagnosis
of ARDS was a challenge inherent to all studies of diag-
nostic testing for this syndrome regardless of the new
Berlin definition used. Finally, we did not test the con-
centration of TF in alveolar fluid and lack an extended
comparison with other biomarkers of ALI/ARDS.
Conclusions
In this study, TF level in the patients with sepsis-
induced ARDS was significantly higher than that of non-
ARDS patients. And, it was associated with the clinical
severity of ARDS according to the new Berlin definition.
Thus, the present study provided further evidence about
TF as a valuable diagnostic biomarker for the diagnosis
of sepsis-induced ARDS. The plasma TF levels in com-
bination with APACHE II scores were a strong prognos-
tic predictor for patients with severe sepsis.
Key messages
The present study delivered strong evidence about TF as
a valuable diagnostic biomarker for the diagnosis of
sepsis-induced ARDS.APACHE II scores and plasma TF levels at enrollment
were the common predictors of 30-day mortality in pa-
tients with severe sepsis.
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